在胃癌中用于药物重定向的可向途径
Alba Valero-Almingol1, Sheyla Montori1, Nayra Felípez1
1Gastroenterology Research Unit, Instituto de Investigación Sanitaria de Navarra, Navarrabiomed, Universidad Pública de Navarra, Hospital Universitario de Navarra, Pamplona 31008, Navarre, Spain.
World journal of gastroenterology
|November 3, 2025
概括
药物再利用为开发新的胃癌 (GC) 治疗提供了一个具有成本效益的策略. 本综述探讨了针对新型GC疗法的Wnt/β-catenin等关键途径.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 胃癌 (GC) 是全球癌症相关死亡的主要原因,通常在晚期被诊断出来.
- 有限的早期症状和非特异性的晚期表现有助于预后不佳和低生存率.
- 目前的治疗选择是不够的,突出需要创新的治疗策略.
研究的目的:
- 审查涉及胃癌 (GC) 发展的关键分子通路.
- 探索药物重定向的潜力,以准GC中的这些途径.
- 确定新且具有成本效益的GC治疗方法的有希望的途径.
主要方法:
- 关于胃癌途径和药物重新用途的科学文章的文献综述.
- 对参与GC病变发生的关键信号通路的分析.
- 识别已批准的药物,这些药物有可能对这些途径进行重用.
主要成果:
- 一些途径,包括MAPK,PI3K/AKT/mTOR和Wnt/β-catenin,对于GC进展至关重要.
- 由于成本降低和开发时间表,药物再利用是一个可行的策略.
- 用重新定位的药物准这些途径为新的GC疗法提供了一个有希望的方法.
结论:
- 重新利用现有药物以准关键分子通路是推动胃癌治疗的有希望的策略.
- 对药物再利用的进一步研究可以为GC患者带来更容易获得和更有效的疗法.
- 这种方法有可能提高生存率并克服当前GC治疗的局限性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
556
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
556


